Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
IFRX 
InflaRx N.V. (IFRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: IFRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.31
1 Year Target Price $10.31
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -69.96% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 70.46M USD | Price to earnings Ratio - | 1Y Target Price 10.31 |
Price to earnings Ratio - | 1Y Target Price 10.31 | ||
Volume (30-day avg) 7 | Beta 1.46 | 52 Weeks Range 0.71 - 2.77 | Updated Date 01/9/2026 |
52 Weeks Range 0.71 - 2.77 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -42015.19% |
Management Effectiveness
Return on Assets (TTM) -40.69% | Return on Equity (TTM) -72.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22849208 | Price to Sales(TTM) 1121.23 |
Enterprise Value 22849208 | Price to Sales(TTM) 1121.23 | ||
Enterprise Value to Revenue 311.42 | Enterprise Value to EBITDA 0.5 | Shares Outstanding 67747130 | Shares Floating 56940785 |
Shares Outstanding 67747130 | Shares Floating 56940785 | ||
Percent Insiders 6.38 | Percent Institutions 27.69 |
Upturn AI SWOT
InflaRx N.V.
Company Overview
History and Background
InflaRx N.V. is a clinical-stage biopharmaceutical company founded in 2007. It focuses on developing novel therapeutics for inflammatory diseases. A significant milestone was its IPO in 2015. The company's evolution has been driven by its lead product candidate, Riximyou00ae (INF-001), and its research into C5a inhibition.
Core Business Areas
- Drug Development: InflaRx's core business is the discovery and development of highly selective inhibitors of the complement factor C5a. This pathway is implicated in various inflammatory and autoimmune diseases.
Leadership and Structure
InflaRx N.V. is led by a management team with extensive experience in the biopharmaceutical industry. Key figures include the CEO and CSO. The company operates as a biopharmaceutical research and development entity.
Top Products and Market Share
Key Offerings
- Product Name 1: Riximyou00ae (INF-001) - Description: Riximyou00ae is a novel, investigational monoclonal antibody targeting C5a, designed to block the pro-inflammatory effects of C5a. It is being developed for various inflammatory conditions, including hidradenitis suppurativa (HS) and bullous pemphigoid (BP). Market Share Data: As an investigational drug, Riximyou00ae does not currently have market share. Competitors: While not a direct competitor for Riximyo's specific indications, other companies developing treatments for HS and BP include AbbVie (Humira), Pfizer (Xeljanz), and Eli Lilly (Olumiant). Companies developing C5 inhibitors include Alexion Pharmaceuticals (Soliris, Ultomiris) for different indications.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on inflammatory and autoimmune diseases, is characterized by high research and development costs, long drug development cycles, and significant regulatory hurdles. There is a constant demand for novel therapies with improved efficacy and safety profiles. The market is competitive, with both large pharmaceutical companies and smaller biotech firms vying for market share.
Positioning
InflaRx positions itself as a leader in C5a inhibition, aiming to address unmet medical needs in inflammatory diseases. Its competitive advantage lies in its selective C5a inhibition approach, potentially offering a differentiated therapeutic profile compared to broader immunosuppressants or other complement inhibitors.
Total Addressable Market (TAM)
The TAM for inflammatory and autoimmune diseases is vast, encompassing hundreds of millions of patients globally. For specific indications like hidradenitis suppurativa and bullous pemphigoid, the TAM is in the billions of dollars. InflaRx is positioned to capture a significant portion of this TAM with successful development and commercialization of Riximyou00ae for its target indications.
Upturn SWOT Analysis
Strengths
- Proprietary C5a inhibition platform
- Lead product candidate Riximyou00ae (INF-001) with promising clinical data
- Experienced management team
- Focus on significant unmet medical needs
Weaknesses
- Clinical-stage company with no approved products
- Dependence on the success of Riximyou00ae
- Significant funding requirements for ongoing development and potential commercialization
- Limited pipeline diversification
Opportunities
- Potential to secure regulatory approvals for Riximyou00ae in key indications
- Expansion of Riximyou00ae into other inflammatory diseases
- Partnerships or licensing agreements for Riximyou00ae
- Advancements in precision medicine enabling targeted therapies
Threats
- Failure to achieve regulatory approval for Riximyou00ae
- Unforeseen adverse events in clinical trials
- Competition from existing and emerging therapies
- Changes in healthcare policy and reimbursement landscapes
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- Alexion Pharmaceuticals (US Stock Symbol: ALXN - now part of AstraZeneca)
- UCB S.A. (no direct US stock symbol for UCB N.V., but often traded on exchanges)
- Pfizer Inc. (US Stock Symbol: PFE)
- AbbVie Inc. (US Stock Symbol: ABBV)
Competitive Landscape
InflaRx faces intense competition from established pharmaceutical companies with approved therapies for inflammatory diseases. Its advantage lies in its novel C5a inhibition mechanism, which, if validated and approved, could offer a distinct treatment option. However, competitors have broader pipelines and greater commercial resources.
Growth Trajectory and Initiatives
Historical Growth: InflaRx's historical growth has been characterized by the advancement of its Riximyou00ae program through clinical trial phases and the expansion of its research into C5a inhibition. This growth is measured by pipeline progression rather than revenue growth.
Future Projections: Future projections are heavily reliant on the clinical trial outcomes and subsequent regulatory approvals for Riximyou00ae. Analyst estimates would likely focus on the potential peak sales of Riximyou00ae and the probability of success for its pipeline.
Recent Initiatives: Recent initiatives would include the progression of Riximyou00ae in ongoing clinical trials for indications such as hidradenitis suppurativa and bullous pemphigoid, and potential collaborations or strategic partnerships.
Summary
InflaRx N.V. is a biopharmaceutical company with a promising lead candidate, Riximyou00ae, targeting inflammatory diseases via C5a inhibition. Its strengths lie in its innovative platform and potential to address unmet needs. However, it faces significant risks as a clinical-stage company dependent on regulatory approval and without current revenue. Key challenges include high R&D costs, competition, and funding needs. Success hinges on successful clinical trials and market penetration.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Financial News Outlets
- Industry Analyst Reports
- Biopharmaceutical Market Research Databases
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Stock market data and company performance can be volatile. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InflaRx N.V.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2017-11-08 | Co-Founder, CEO & Executive Director Dr. Niels C. Riedemann M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://www.inflarx.de |
Full time employees 74 | Website https://www.inflarx.de | ||
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.